Title:
RECOMBINANT FUSION PROTEIN TARGETING PD-L1 AND VEGF, AND PREPARATION AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/232022
Kind Code:
A1
Abstract:
The present application provides a recombinant fusion protein, comprising 1) a PD-L1 antibody or an antigen-binding fragment thereof, and 2) a VEGF-binding peptide, the N-terminus of a heavy chain or a light chain of the PD-L1 antibody or the antigen-binding fragment thereof being connected to the VEGF-binding peptide by means of a linker. Also provided are a nucleic acid molecule encoding the recombinant fusion protein, an expression vector comprising the nucleic acid molecule, a method for preparing the recombinant fusion protein, and a method for using the recombinant fusion protein to treat diseases associated with the PD-L1 and/or VEGF pathway.
Inventors:
TIAN WENZHI (CN)
LI SONG (CN)
CHEN DIANZE (CN)
YANG CHUNMEI (CN)
ZHU WENQI (CN)
LI SONG (CN)
CHEN DIANZE (CN)
YANG CHUNMEI (CN)
ZHU WENQI (CN)
Application Number:
PCT/CN2023/097088
Publication Date:
December 07, 2023
Filing Date:
May 30, 2023
Export Citation:
Assignee:
IMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC (CN)
International Classes:
C07K19/00; A61K38/17; A61K39/395; A61P1/16; A61P27/02; A61P35/00; C07K16/28; C12N15/62; C12N15/63
Domestic Patent References:
| WO2022042719A1 | 2022-03-03 | |||
| WO2022068894A1 | 2022-04-07 |
Foreign References:
| CN113166258A | 2021-07-23 | |||
| CN113773401A | 2021-12-10 | |||
| CN109575140A | 2019-04-05 |
Attorney, Agent or Firm:
CHENG & PENG INTELLECTUAL PROPERTY LAW OFFICE (CN)
Download PDF: